1
|
Chiappella A, Guidetti A, Dodero A, Bramanti S, Zinzani P, Santoro A, Casadei B, Di Rocco A, Carrabba M, Chiusolo P, Martino M, Barbui AM, Tisi MC, Miceli R, Carniti C, Corradini P. FIRST REPORT OF THE REAL‐LIFE PROSPECTIVE OBSERVATIONAL STUDY “CAR‐T CELL IN DIFFUSE LARGE B‐CELL AND PRIMARY MEDIASTINAL LYMPHOMAS” OF THE ITALIAN SOCIETY OF HEMATOLOGY. Hematol Oncol 2021. [DOI: 10.1002/hon.187_2880] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- A. Chiappella
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Hematology and Stem Cell Transplantation Milano Italy
| | - A. Guidetti
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Hematology and Stem Cell Transplantation Milano Italy
| | - A. Dodero
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Hematology and Stem Cell Transplantation Milano Italy
| | - S. Bramanti
- Humanitas Clinical and Research Center IRCCS Hematology Rozzano Italy
| | - P. Zinzani
- University of Bologna Institute of Hematology "Seràgnoli" Bologna Italy
| | - A. Santoro
- Humanitas Clinical and Research Center IRCCS Hematology Rozzano Italy
| | - B. Casadei
- University of Bologna Institute of Hematology "Seràgnoli" Bologna Italy
| | - A. Di Rocco
- 'Sapienza' University of Rome Department of Translational and Precision Medicine Roma Italy
| | - M. Carrabba
- San Raffaele Hospital IRCCS Hematology and Bone Marrow Transplantation Unit Milano Italy
| | - P. Chiusolo
- Fondazione Policlinico Universitario A. Gemelli IRCCS Università Cattolica del Sacro Cuore Department of Diagnostica per Immagini Radioterapia Oncologica ed Ematologia Hematology Section Department of Scienze Radiologiche ed Ematologiche Roma Italy
| | - M. Martino
- Grande Ospedale Metropolitano “Bianchi‐Melacrino‐Morelli” Stem Cell Transplant and Cellular Therapies Unit Reggio Calabria Italy
| | - A. M. Barbui
- Azienda Socio Sanitaria Territoriale (ASST), Ospedale Papa Giovanni XXIII Hematology Unit Bergamo Italy
| | - M. C. Tisi
- San Bortolo Hospital Cell Therapy and Hematology Vicenza Italy
| | - R. Miceli
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Unit of Clinical Epidemiology and Trial Organization Department of Applied Research and Technological Development Milano Italy
| | - C. Carniti
- Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Italy Laboratory of Hematology Division of Hematology and Stem Cell Transplantation Milano Italy
| | - P. Corradini
- Chair of Hematology University of Milano Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Division of Hematology and Stem Cell Transplantation Milano Italy
| |
Collapse
|
2
|
Scarisbrick JJ, Quaglino P, Prince HM, Papadavid E, Hodak E, Bagot M, Servitje O, Berti E, Ortiz-Romero P, Stadler R, Patsatsi A, Knobler R, Guenova E, Child F, Whittaker S, Nikolaou V, Tomasini C, Amitay I, Prag Naveh H, Ram-Wolff C, Battistella M, Alberti-Violetti S, Stranzenbach R, Gargallo V, Muniesa C, Koletsa T, Jonak C, Porkert S, Mitteldorf C, Estrach T, Combalia A, Marschalko M, Csomor J, Szepesi A, Cozzio A, Dummer R, Pimpinelli N, Grandi V, Beylot-Barry M, Pham-Ledard A, Wobser M, Geissinger E, Wehkamp U, Weichenthal M, Cowan R, Parry E, Harris J, Wachsmuth R, Turner D, Bates A, Healy E, Trautinger F, Latzka J, Yoo J, Vydianath B, Amel-Kashipaz R, Marinos L, Oikonomidi A, Stratigos A, Vignon-Pennamen MD, Battistella M, Climent F, Gonzalez-Barca E, Georgiou E, Senetta R, Zinzani P, Vakeva L, Ranki A, Busschots AM, Hauben E, Bervoets A, Woei-A-Jin FJSH, Matin R, Collins G, Weatherhead S, Frew J, Bayne M, Dunnill G, McKay P, Arumainathan A, Azurdia R, Benstead K, Twigger R, Rieger K, Brown R, Sanches JA, Miyashiro D, Akilov O, McCann S, Sahi H, Damasco FM, Querfeld C, Folkes A, Bur C, Klemke CD, Enz P, Pujol R, Quint K, Geskin L, Hong E, Evison F, Vermeer M, Cerroni L, Kempf W, Kim Y, Willemze R. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol 2019; 181:350-357. [PMID: 30267549 DOI: 10.1111/bjd.17258] [Citation(s) in RCA: 112] [Impact Index Per Article: 22.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/25/2018] [Indexed: 12/16/2022]
Abstract
BACKGROUND Survival in mycosis fungoides (MF) is varied and may be poor. The PROCLIPI (PROspective Cutaneous Lymphoma International Prognostic Index) study is a web-based data collection system for early-stage MF with legal data-sharing agreements permitting international collaboration in a rare cancer with complex pathology. Clinicopathological data must be 100% complete and in-built intelligence in the database system ensures accurate staging. OBJECTIVES To develop a prognostic index for MF. METHODS Predefined datasets for clinical, haematological, radiological, immunohistochemical, genotypic, treatment and quality of life are collected at first diagnosis of MF and annually to test against survival. Biobanked tissue samples are recorded within a Federated Biobank for translational studies. RESULTS In total, 430 patients were enrolled from 29 centres in 15 countries spanning five continents. Altogether, 348 were confirmed as having early-stage MF at central review. The majority had classical MF (81·6%) with a CD4 phenotype (88·2%). Folliculotropic MF was diagnosed in 17·8%. Most presented with stage I (IA: 49·4%; IB: 42·8%), but 7·8% presented with enlarged lymph nodes (stage IIA). A diagnostic delay between first symptom development and initial diagnosis was frequent [85·6%; median delay 36 months (interquartile range 12-90)]. This highlights the difficulties in accurate diagnosis, which includes lack of a singular diagnostic test for MF. CONCLUSIONS This confirmed early-stage MF cohort is being followed-up to identify prognostic factors, which may allow better management and improve survival by identifying patients at risk of disease progression. This study design is a useful model for collaboration in other rare diseases, especially where pathological diagnosis can be complex.
Collapse
Affiliation(s)
- J J Scarisbrick
- European Co-ordinating PROCLIPI Centre for PROCLIPI, University Hospitals Birmingham, Birmingham, U.K
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
- Member of the UK Cutaneous Lymphoma Group
| | - P Quaglino
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - H M Prince
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - E Papadavid
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - E Hodak
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - M Bagot
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - O Servitje
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - E Berti
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - P Ortiz-Romero
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Stadler
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - A Patsatsi
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Knobler
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - E Guenova
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - F Child
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the UK Cutaneous Lymphoma Group
| | - S Whittaker
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
- Member of the UK Cutaneous Lymphoma Group
| | - V Nikolaou
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - C Tomasini
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - I Amitay
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - H Prag Naveh
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - C Ram-Wolff
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M Battistella
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - S Alberti-Violetti
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - R Stranzenbach
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - V Gargallo
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - C Muniesa
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - T Koletsa
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - C Jonak
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - S Porkert
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - C Mitteldorf
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - T Estrach
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Combalia
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M Marschalko
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - J Csomor
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Szepesi
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Cozzio
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Dummer
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - N Pimpinelli
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - V Grandi
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M Beylot-Barry
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Pham-Ledard
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M Wobser
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - E Geissinger
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - U Wehkamp
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - M Weichenthal
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - R Cowan
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the UK Cutaneous Lymphoma Group
| | - E Parry
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the UK Cutaneous Lymphoma Group
| | - J Harris
- Member of the UK Cutaneous Lymphoma Group
| | - R Wachsmuth
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the UK Cutaneous Lymphoma Group
| | - D Turner
- Member of the UK Cutaneous Lymphoma Group
| | - A Bates
- Member of the UK Cutaneous Lymphoma Group
| | - E Healy
- Member of the UK Cutaneous Lymphoma Group
| | - F Trautinger
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - J Latzka
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - J Yoo
- European Co-ordinating PROCLIPI Centre for PROCLIPI, University Hospitals Birmingham, Birmingham, U.K
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - B Vydianath
- European Co-ordinating PROCLIPI Centre for PROCLIPI, University Hospitals Birmingham, Birmingham, U.K
| | - R Amel-Kashipaz
- European Co-ordinating PROCLIPI Centre for PROCLIPI, University Hospitals Birmingham, Birmingham, U.K
| | - L Marinos
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Oikonomidi
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Stratigos
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M-D Vignon-Pennamen
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M Battistella
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - F Climent
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - E Gonzalez-Barca
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - E Georgiou
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - R Senetta
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - P Zinzani
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - L Vakeva
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Ranki
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A-M Busschots
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - E Hauben
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Bervoets
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - F J S H Woei-A-Jin
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - R Matin
- Member of the UK Cutaneous Lymphoma Group
| | - G Collins
- Member of the UK Cutaneous Lymphoma Group
| | | | - J Frew
- Member of the UK Cutaneous Lymphoma Group
| | - M Bayne
- Member of the UK Cutaneous Lymphoma Group
| | - G Dunnill
- Member of the UK Cutaneous Lymphoma Group
| | - P McKay
- Member of the UK Cutaneous Lymphoma Group
| | | | - R Azurdia
- Member of the UK Cutaneous Lymphoma Group
| | - K Benstead
- Member of the UK Cutaneous Lymphoma Group
| | - R Twigger
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - K Rieger
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Brown
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - J A Sanches
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - D Miyashiro
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - O Akilov
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - S McCann
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - H Sahi
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - F M Damasco
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - C Querfeld
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - A Folkes
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - C Bur
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - C-D Klemke
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - P Enz
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Pujol
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - K Quint
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - L Geskin
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - E Hong
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - F Evison
- European Co-ordinating PROCLIPI Centre for PROCLIPI, University Hospitals Birmingham, Birmingham, U.K
| | - M Vermeer
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - L Cerroni
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - W Kempf
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - Y Kim
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Willemze
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| |
Collapse
|
3
|
Zinzani P, Samaniego F, Jurczak W, Lech-Maranda E, Ghosh N, Anz B, Patten P, Reeves J, Leslie L, Smolewski P, Chavez J, Scarfo L, Derenzini E, Burke J, Sharman J, Kolibaba K, O'Connor O, Cheah C, Miskin H, Sportelli P, Weiss M, Fowler N. UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN-LABEL, REGISTRATION DIRECTED PHASE 2 STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.139_2629] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- P. Zinzani
- Institute of Hematology; "L. e A. Seragnoli" University of Bologna; Bologna Italy
| | - F. Samaniego
- Department of Lymphoma/ Myeloma; MD Anderson Cancer Center; Houston United States
| | - W. Jurczak
- Department of Hematology; Jagiellonian University; Krakow Poland
| | - E. Lech-Maranda
- Department of Hematology; Institute of Hematology and Transfusion Medicine; Warsaw Poland
| | - N. Ghosh
- Department of Hematologic Oncology and Blood Disorders; Levine Cancer Center; Charlotte United States
| | - B. Anz
- Tennessee Oncology; Sarah Cannon Research Institute; Chattanooga United States
| | - P. Patten
- Department of Hematology; Kings Hospital NHS Foundation Trust; London United Kingdom
| | - J. Reeves
- Florida Cancer Specialists; Sarah Cannon Research Institute; Fort Myers United States
| | - L.A. Leslie
- John Theurer Cancer Center; Hackensack University Medical Center; Hackensack United States
| | - P. Smolewski
- Department of Hematology; Copernicus Memorial Hospital; Lodz Poland
| | - J.C. Chavez
- Department of Hematology; H. Lee Moffitt Cancer Center and Research Institute; Tampa United States
| | - L. Scarfo
- IRCCS Ospedale San Raffaele; Università Vita-Salute San Raffaele; Milan Italy
| | - E. Derenzini
- Department of Hematology; European Institute of Oncology; Milan Italy
| | - J.M. Burke
- Rocky Mountain Cancer Centers; US Oncology; Aurora United States
| | - J. Sharman
- Willamette Valley Cancer Institute; US Oncology; Eugene United States
| | - K. Kolibaba
- Compass Oncology; US Oncology; Vancouver United States
| | - O.A. O'Connor
- Center for Lymphoid Malignancies; Columbia University Medical Center; New York United States
| | - C.Y. Cheah
- Department of Hematology; Sir Charles Gairdner Hospital; Perth Australia
| | - H.P. Miskin
- Drug Development; TG Therapeutics; New York United States
| | - P. Sportelli
- Drug Development; TG Therapeutics; New York United States
| | - M.S. Weiss
- Drug Development; TG Therapeutics; New York United States
| | - N.H. Fowler
- Department of Lymphoma/ Myeloma; MD Anderson Cancer Center; Houston United States
| |
Collapse
|
4
|
Tiacci E, De Carolis L, Simonetti E, Zaja F, Capponi M, Ambrosetti A, Lucia E, Antolino A, Pulsoni A, Ferrari S, Zinzani P, Rigacci L, Gaidano G, Della Seta R, Frattarelli N, Falcucci P, Visani G, Foà R, Falini B. THE BRAF INHIBITOR VEMURAFENIB PLUS RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.72_2629] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- E. Tiacci
- Institute of Hematology and Center for Hemato-Oncology Research; University and Hospital of Perugia; Perugia Italy
| | - L. De Carolis
- Institute of Hematology and Center for Hemato-Oncology Research; University and Hospital of Perugia; Perugia Italy
| | - E. Simonetti
- Institute of Hematology and Center for Hemato-Oncology Research; University and Hospital of Perugia; Perugia Italy
| | - F. Zaja
- Hematology Unit; Azienda Sanitaria Universitaria Integrata-Ospedale Maggiore; Trieste Italy
| | - M. Capponi
- Institute of Hematology and Center for Hemato-Oncology Research; University and Hospital of Perugia; Perugia Italy
| | - A. Ambrosetti
- Department of Medicine; Section of Hematology; Verona Italy
| | - E. Lucia
- Hematology Unit; Ospedale di Cosenza; Cosenza Italy
| | - A. Antolino
- Hematology Unit, Department of Transfusional Medicine - SIMMT; Maria Paternò-Arezzo Hospital; Ragusa Italy
| | - A. Pulsoni
- Hematology Unit, Department of Translational and Precision Medicine; "Sapienza" University of Rome; Roma Italy
| | - S. Ferrari
- Department of Hematology; Spedali Civili di Brescia; Brescia Italy
| | - P. Zinzani
- Institute of Hematology, Policlinico Sant'Orsola-Malpighi; University of Bologna; Bologna Italy
| | - L. Rigacci
- Hematology and Stem Cell Transplant Unit; AO San Camillo Forlanini; Roma Italy
| | - G. Gaidano
- Department of Translational Medicine, Division of Hematology; Amedeo Avogadro University of Eastern Piedmont; Novara Italy
| | | | | | - P. Falcucci
- Hematology Unit; Ospedale di Ronciglione; Viterbo Italy
| | - G. Visani
- Hematology Unit; Ospedale di Pesaro; Pesaro Italy
| | - R. Foà
- Hematology Unit, Department of Translational and Precision Medicine; "Sapienza" University of Rome; Roma Italy
| | - B. Falini
- Institute of Hematology and Center for Hemato-Oncology Research; University and Hospital of Perugia; Perugia Italy
| |
Collapse
|
5
|
Jacobsen E, Ďuraš J, Ardeshna K, Cherry M, Offner F, Mayer J, Bijou F, Tani M, Musuraca G, Merli M, Marasca R, Weaver D, Lustgarten S, Youssoufian H, Zinzani P. CHARACTERIZATION OF DUVELISIB IN PATIENTS WITH REFRACTORY MARGINAL ZONE LYMPHOMA: DATA FROM THE PHASE 2 DYNAMO TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.70_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- E. Jacobsen
- Department of Medical Oncology; Dana-Farber Cancer Institute; Boston MA United States
| | - J. Ďuraš
- University Hospital Ostrava and Faculty of Medicine; University Hospital Ostrava; Ostrava Czech Republic
| | - K. Ardeshna
- Department of Oncology; University College London Hospitals National Health Service Foundation Trust; London United Kingdom
| | - M. Cherry
- Department of Medical Oncology; Atlantic Health Systems; Morristown NJ United States
| | - F. Offner
- Department of Hematology; University Hospital Ghent; Gent Belgium
| | - J. Mayer
- Department of Internal Medicine; Fakultní Nemocnice Brno; Brno Czech Republic
| | - F. Bijou
- Department of Medical Oncology; Institut Bergonie; Boredeaux France
| | - M. Tani
- Hematology Unit; Santa Maria delle Croci Hospital; Ravenna Italy
| | - G. Musuraca
- Hematology Unit; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori; Meldola Italy
| | - M. Merli
- Department of Hematology; Ospedale di Circolo e Fondazione Macchi; Varese Italy
| | - R. Marasca
- Department of Medical Sciences; Section of Hematology, Università di Modena e Reggio Emilia; Modena Italy
| | - D.T. Weaver
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - S. Lustgarten
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - H. Youssoufian
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - P. Zinzani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| |
Collapse
|
6
|
Zinzani P, Turner D, Marshall S, Conteh V, Kang H, Kim S, Lee Y, Bishton M. REAL WORLD EFFECTIVENESS AND SAFETY OF CT-P10 IN DIFFUSE LARGE B-CELL LYMPHOMA: INTERIM RESULTS FROM A EUROPEAN NON-INTERVENTIONAL POST-AUTHORISATION SAFETY STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.121_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- P. Zinzani
- Institute of Hematology “Seràgnoli”; University of Bologna; Bologna Italy
| | - D.L. Turner
- Department of Haematology; Torbay and South Devon NHS Foundation Trust; Torquay United Kingdom
| | - S.R. Marshall
- Department of Haematology; Sunderland Royal Hospital, City Hospitals Sunderland NHS Trust; Sunderland United Kingdom
| | - V. Conteh
- Cancer Services; Royal Free London NHS Foundation Trust, Barnet Hospital; Barnet United Kingdom
| | - H. Kang
- Medical Affairs; Celltrion Healthcare; Incheon Republic of Korea
| | - S. Kim
- Medical Affairs; Celltrion Healthcare; Incheon Republic of Korea
| | - Y. Lee
- Medical Affairs; Celltrion Healthcare; Incheon Republic of Korea
| | - M.J. Bishton
- Department of Haematology; Nottingham City Hospital; Nottingham United Kingdom
| |
Collapse
|
7
|
Awan F, Chan R, Gu L, Xing G, Bhargava P, Ruzicka B, Dreyling M, Zinzani P, Gopal A. TREATMENT EMERGENT ADVERSE EVENTS VARY WITH DIFFERENT PI3K INHIBITORS. Hematol Oncol 2019. [DOI: 10.1002/hon.208_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- F.T. Awan
- Harold C. Simmons Comprehensive Cancer Center; University of Texas Southwestern Medical Center; Dallas United States
| | - R.J. Chan
- Medical Affairs; Gilead Sciences, Inc.; Foster City United States
| | - L. Gu
- Biostatistics; Gilead Sciences, Inc.; Seattle United States
| | - G. Xing
- Biostatistics; Gilead Sciences, Inc.; Seattle United States
| | - P. Bhargava
- Medical Affairs; Gilead Sciences, Inc.; Foster City United States
| | - B. Ruzicka
- Medical Affairs; Gilead Sciences, Inc.; Foster City United States
| | - M. Dreyling
- Department of Medicine III; University Hospital of the Ludwig Maximilians University Munich; München Germany
| | - P. Zinzani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - A.K. Gopal
- Fred Hutchinson Cancer Research Center; Seattle Cancer Care Alliance, University of Washington; Seattle United States
| |
Collapse
|
8
|
Zelenetz A, Zinzani P, Buske C, Ribrag V, Cunningham D, Jurczak W, Abrisqueta P, Agajanian R, Chaudhry A, Kayyal T, Wood J, Llorin-Sangalang J, Brown J. A PIVOTAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TWO-ARM, PHASE 2 STUDY OF ME-401 INVESTIGATING TWO DOSING SCHEDULES IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AFTER FAILURE OF TWO OR MORE PRIOR SYSTEMIC THERAPIES. Hematol Oncol 2019. [DOI: 10.1002/hon.2_2632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A. Zelenetz
- Lymphoma Service; Memorial Sloan Kettering Cancer Center; New York United States
| | - P. Zinzani
- Institute of Hematology; University of Bologna; Bologna Italy
| | - C. Buske
- Life Science Gebaeude; Universitatklinikum Ulm; Ulm Germany
| | - V. Ribrag
- Gustave Roussy Cancer Center; Institut Gustave Roussy; Villejuif France
| | - D. Cunningham
- Lymphoma Unit; Royal Marsden Hospital NHS; Sutton United Kingdom
| | - W. Jurczak
- Department of Hematology; Jagiellonian University; Kraków Poland
| | - P. Abrisqueta
- Department of Hematology; Hospital Vall Hebron; Barcelona Spain
| | - R. Agajanian
- Department of Hematology; The Oncology Institute of Hope and Innovation; Cerritos United States
| | - A. Chaudhry
- Medical Oncology/Hematology; Medical Oncology Associates PS; Spokane United States
| | - T. Kayyal
- Department of Oncology/Hematology; Renovatio Clinical; The Woodlands United States
| | - J. Wood
- Medical Affairs; MEI Pharma, Inc.; San Diego United States
| | | | - J. Brown
- Division of Hematologic Malignancies; Dana Farber Cancer Institute; Boston United States
| |
Collapse
|
9
|
Marangon M, Morigi A, Casadei B, Broccoli A, Nanni L, Stefoni V, Argnani L, Lolli G, Carella M, Zinzani P. 90
Y-IBRITUMOMAB TIUXETAN IN PATIENTS WITH EXTRA-NODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT LYMPHOMA) - THE ZENO STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.72_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- M. Marangon
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - A. Morigi
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - B. Casadei
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - A. Broccoli
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - L. Nanni
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - V. Stefoni
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - L. Argnani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - G. Lolli
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - M. Carella
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - P. Zinzani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| |
Collapse
|
10
|
Bishton M, Marshall S, Conteh V, Rodríguez Fernández A, Kang H, Kim S, Lee Y, Zinzani P. CT-P10 RAPID INFUSION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA OR CHRONIC LYMPHOCYTIC LEUKAEMIA: INTERIM RESULTS FROM A NON-INTERVENTIONAL POST-AUTHORISATION SAFETY STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.224_2631] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Bishton
- Department of Haematology; City Hospital Nottingham; Nottingham United Kingdom
| | - S.R. Marshall
- Department of Haematology; Sunderland Royal Hospital, City Hospitals Sunderland NHS Trust; Sunderland United Kingdom
| | - V. Conteh
- Cancer Services; Royal Free London NHS Foundation Trust, Barnet Hospital; Barnet United Kingdom
| | | | - H. Kang
- Medical Affairs; Celltrion Healthcare; Incheon Republic of Korea
| | - S. Kim
- Medical Affairs; Celltrion Healthcare; Incheon Republic of Korea
| | - Y. Lee
- Medical Affairs; Celltrion Healthcare; Incheon Republic of Korea
| | - P. Zinzani
- Institute of Hematology “Seràgnoli”; University of Bologna; Bologna Italy
| |
Collapse
|
11
|
Porcu P, Kim Y, Zinzani P, Sicard H, Azim H, Bagot M. TELLOMAK: T-CELL LYMPHOMA ANTI-KIR3DL2 THERAPY: AN OPEN LABEL, MULTI-COHORT, MULTI-CENTER, INTERNATIONAL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF IPH4102 ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH ADVANCED T-CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.40_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- P. Porcu
- Medical Oncology; Sidney Kimmel Cancer Center, Thomas Jefferson University; Philadelphia United States
| | - Y. Kim
- Dermatology; Stanford Cancer Institute; San Francisco United States
| | - P. Zinzani
- Hematology/Oncology; University of Bologna; Bologna Italy
| | - H. Sicard
- Research and Development; Innate Pharma; Marseille France
| | - H.A. Azim
- Research and Development; Innate Pharma; Marseille France
| | - M. Bagot
- Dermatology; Hôpital Saint Louis; Paris France
| |
Collapse
|
12
|
Illidge T, Horwitz S, Iyer S, Bartlett N, Kim W, Tilly H, Belada D, Feldman T, Illés Á, Jacobsen E, Hüttmann A, Zinzani P, O'Connor O, Trepicchio W, Miao H, Rao S, Onsum M, Manley T, Advani R. RESPONSE TO A+CHP BY CD30 EXPRESSION IN THE ECHELON-2 TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.92_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- T. Illidge
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health; University of Manchester, National Institutes of Health and Research Biomedical Research Centre, Manchester Academic Health Sciences Centre, Christie Hospital National Health Service Foundation Trust; Manchester United Kingdom
| | - S. Horwitz
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - S. Iyer
- Department of Lymphoma and Myeloma; Division of Cancer Medicine, MD Anderson Cancer Center; Houston United States
| | - N. Bartlett
- Department of Medicine; Oncology Division, Washington University School of Medicine, Siteman Cancer Center; Saint Louis United States
| | - W. Kim
- Division of Hematology-Oncology; Department of Medicine, Samsung Medical Center; Seoul Republic of Korea
| | - H. Tilly
- Department of Hematology; Centre Henri Becquerel, Université of Rouen Normandie; Rouen France
| | - D. Belada
- 4th Department of Internal Medicine - Haematology; Charles University, Hospital and Faculty of Medicine; Hradec Králové Czech Republic
| | - T. Feldman
- Hematology Division; Hackensack University Medical Center; Hackensack United States
| | - Á. Illés
- Department of Hematology; University of Debrecen, Faculty of Medicine; Debrecen Hungary
| | - E. Jacobsen
- Division of Hematologic Malignancies; Dana-Farber Cancer Institute; Boston United States
| | - A. Hüttmann
- Department of Haematology; Universitatsklinikum Essen; Essen Germany
| | - P. Zinzani
- Institute of Hematology; “Seràgnoli” University of Bologna; Bologna France
| | - O.A. O'Connor
- Department of Medicine; Columbia University Medical Center; New York United States
| | - W. Trepicchio
- Clinical Development; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceuticals Limited; Cambridge United States
| | - H. Miao
- Clinical Development; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceuticals Limited; Cambridge United States
| | - S. Rao
- Development; Seattle Genetics, Inc.; Bothell United States
| | - M. Onsum
- Development; Seattle Genetics, Inc.; Bothell United States
| | - T. Manley
- Development; Seattle Genetics, Inc.; Bothell United States
| | - R. Advani
- Medicine - Med/Oncology; Stanford Cancer Institute; Stanford United States
| |
Collapse
|
13
|
Stefoni V, Broccoli A, Botto B, Corradini P, Pinto A, Re A, Vitolo U, Fanti S, Argnani L, Zinzani P. FIRST SALVAGE TREATMENT WITH BENDAMUSTINE AND BRENTUXIMAB VEDOTIN IN HODGKIN LYMPHOMA: A PHASE 2 STUDY OF FIL ONLUS. Hematol Oncol 2019. [DOI: 10.1002/hon.105_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- V. Stefoni
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - A. Broccoli
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - B. Botto
- Hematology; Department of Oncology, University Hospital Città della Salute e della Scienza; Turin Italy
| | - P. Corradini
- IRCCS Istituto Nazionale dei Tumori; University of Milano; Milan Italy
| | - A. Pinto
- Hematology-Oncology and Stem Cell Transplantation Unit; National Cancer Institute, Fondazione Pascale; Naples Italy
| | - A. Re
- Hematology; Azienda socio-sanitaria territoriale, Ospedali Civili di Brescia; Brescia Italy
| | - U. Vitolo
- Hematology; Department of Oncology, University Hospital Città della Salute e della Scienza; Turin Italy
| | - S. Fanti
- Nuclear Medicine; Medicina Nucleare Metropolitana, Sant'Orsola-Malpighi Hospital, University of Bologna; Bologna Italy
| | - L. Argnani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - P. Zinzani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| |
Collapse
|
14
|
Bruscaggin A, Mollejo M, Tapia G, Gomes da Silva M, Novak U, Dietrich S, Ponzoni M, Rambaldi A, Corradini P, Vitolo U, Merli M, Tzankov A, Cogliatti S, Montalban C, Marasca R, de Leval L, Visco C, Baptista M, Tousseyn T, Facchetti F, Paulli M, Mazzucchelli L, Bea S, Oscier D, Zinzani P, Bhagat G, Inghirami G, Gaidano G, Traverse-Glehen A, Thieblemont C, Piris M, Cavalli F, Arcaini L, Zucca E, Rossi D. MULTI-OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) - INTERIM ANALYSIS OF IELSG46 STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.138_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
15
|
Pinto A, De Filippi R, Zinzani P, Driessen C, Tun H, Hilgier K, Remmy D, Mehrling T, O'Connor O. A FIRST-IN-HUMAN TRIAL OF THE NOVEL MULTI-ACTION THERAPY TINOSTAMUSTINE (EDO-S101) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) HODGKIN LYMPHOMA (HL). Hematol Oncol 2019. [DOI: 10.1002/hon.137_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A. Pinto
- Department of Hematology; University Federico II; Naples Italy
| | - R. De Filippi
- Department of Clinical Medicine and Surgery; University Federico II; Naples Italy
| | - P. Zinzani
- Department of Experimental; Diagnostic and Specialty Medicine, University of Bologna; Bologna Italy
| | - C. Driessen
- Interdisziplinäre Medizinische Dienste; Kantonsspital St Gallen; St Gallen Switzerland
| | - H.W. Tun
- Department of Hematology/Oncology; Mayo Clinic Cancer Center; Jacksonville United States
| | - K. Hilgier
- Clinical Development; Mundipharma EDO; Basel Switzerland
| | - D. Remmy
- Clinical Development; Mundipharma EDO; Basel Switzerland
| | - T. Mehrling
- Clinical Development; Mundipharma EDO; Basel Switzerland
| | - O.A. O'Connor
- Department of Medicine; Colombia University Medical Center; New York United States
| |
Collapse
|
16
|
Zinzani P, Wagner-Johnston N, Miller C, Ardeshna K, Tertreault S, Assouline S, Mayer J, Passamonti F, Lunin S, Pettitt A, Nagy Z, Tournilhac O, Abou-Nassar K, Crump M, Jacobsen E, De Vos S, Youssoufian H, Porter J, Prado S, Flinn I. DYNAMO: a PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_57] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- P. Zinzani
- Institute of Hematology Serágnoli; University of Bologna; Bologna Italy
| | | | - C. Miller
- Cancer Institute; St. Agnes Hospital; Baltimore USA
| | - K. Ardeshna
- Cancer Center; University College London; London UK
| | - S. Tertreault
- Department of Hematology; Florida Cancer Specialists Tallahassee; Tallahassee USA
| | - S. Assouline
- Division of Hematology; Jewish General Hospital; Montreal Canada
| | - J. Mayer
- Interni hematologicka; Onkologicka klinika-FN Brno; Brno Czech Republic
| | - F. Passamonti
- Oncology; Ospedale Di Circolo e Fondazione Macchi U.O. Ematologia; Varese Italy
| | - S. Lunin
- Hematology/Oncology; Florida Cancer Specialist Sarasotta; Sarasotta USA
| | - A. Pettitt
- Department of Molecular and Clinical Cancer Medicine, North West Cancer Research Centre; University of Liverpool; Liverpool UK
| | - Z. Nagy
- Belgyogyaszati Klinika; Semmelweis Egyetem, I. sz; Budapest Hungary
| | - O. Tournilhac
- Service d'hématologie; CHU Estaing; Clermont-Ferrand France
| | - K. Abou-Nassar
- Hematology; Centre intégré de santé et de services sociaux de l'Outaouais; Gatineau Canada
| | - M. Crump
- Hematology; Princess Margaret Cancer Center; Toronto Canada
| | - E. Jacobsen
- Hematology and Oncology; Beth Israel Deaconess Medical Center; Boston USA
| | - S. De Vos
- Hematology and Oncology; Ronald Reagan UCLA Medical Center; Los Angeles USA
| | | | - J. Porter
- Clinical Development; Verastem Inc.; Needham USA
| | - S. Prado
- Clinical Development; Verastem Inc.; Needham USA
| | - I. Flinn
- Hematology and Oncology; Sarah Cannon Research Institute; Nashville USA
| |
Collapse
|
17
|
Zinzani P, Thieblemont C, Melnichenko V, Osmanov D, Bouabdallah K, Walewski J, Majlis A, Fogliatto L, Caballero Barrigón M, Christian B, Gulbas Z, Özcan M, Salles G, Shipp M, Balakumaran A, Chlosta S, Chatterjee A, Armand P. Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE-170 phase 2 trial. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_49] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- P. Zinzani
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| | | | - V. Melnichenko
- Hematology; The National Medical Surgical Сentre named after N.I. Pirogov, Moscow; Russian Federation
| | - D. Osmanov
- Russian Academy of Medical Sciences; N.N. Blokhin Russian Oncological Research Center; Moscow Russian Federation
| | - K. Bouabdallah
- Hematology and Cell Therapy; Groupe Hospitalier du Haut Leveque; Pessac France
| | - J. Walewski
- Lymphoid Malignancy; Maria Sklodowska-Curie Institute - Oncology Center; Warsaw Poland
| | - A. Majlis
- Hematology, University of Chile; Hospital del Salvador; Santiago Chile
| | - L. Fogliatto
- Hematology; Hospital de Clinicas de Porto Alegre; Porto Alegre Brazil
| | | | - B. Christian
- Division of Hematology; Ohio State University - James Comprehensive Cancer Center; Columbus USA
| | - Z. Gulbas
- Hematologic Oncology; Anadolu Medical Center; Gebze Turkey
| | - M. Özcan
- Division of Hematology; Ankara University School of Medicine; Ankara Turkey
| | - G.A. Salles
- Hospices Civils de Lyon, Cancer Research Center of Lyon; Claude Bernard University Lyon; Pierre Benite France
| | - M.A. Shipp
- Division of Hematologic Neoplasia; Dana-Farber Cancer Institute; Boston USA
| | | | - S. Chlosta
- Clinical Research; Merck & Co., Inc.; Kenilworth USA
| | - A. Chatterjee
- Clinical Research; Merck & Co., Inc.; Kenilworth USA
| | - P. Armand
- Division of Hematologic Neoplasia; Dana-Farber Cancer Institute; Boston USA
| |
Collapse
|
18
|
Gerecitano J, Santoro A, Leppä S, Kim T, Kim W, Janssens A, Pedersen M, Reis D, Granvil C, Shen J, Zheng H, Childs B, Zinzani P. SAFETY RUN-IN OF COPANLISIB IN COMBINATION WITH RITUXIMAB PLUS BENDAMUSTINE IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN'S LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_187] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- J. Gerecitano
- Lymphoma Service/Developmental Therapy Clinic; Memorial Sloan-Kettering Cancer Center; New York USA
| | - A. Santoro
- Department of Oncology and Hematology; Humanitas Cancer Center, Humanitas Clinical and Research Center; Rozzano (MI) Italy
| | - S. Leppä
- Department of Oncology; Helsinki University Central Hospital Cancer Center; Helsinki Finland
| | - T. Kim
- Department of Internal Medicine; Seoul National University Hospital; Seoul Korea, Republic of
| | - W. Kim
- Division of Hematology and Oncology, Department of Medicine; Sungkyunkwan University School of Medicine, Samsung Medical Center; Seoul Korea, Republic of
| | - A. Janssens
- Dienst Haematologie, UZ Leuven; Leuven Belgium
| | - M. Pedersen
- Department of Hematology, HS Rigshospitalet; Copenhagen Denmark
| | - D. Reis
- Clinical Development, Bayer SA; São Paulo Brazil
| | - C. Granvil
- Clinical Pharmacology; Bayer HealthCare Pharmaceuticals Inc; Whippany NJ USA
| | - J. Shen
- Clinical Statistics; Bayer HealthCare Pharmaceuticals Inc; Whippany NJ USA
| | - H. Zheng
- Clinical Development; Bayer HealthCare Pharmaceuticals Inc; Whippany NJ USA
| | - B.H. Childs
- Clinical Development; Bayer HealthCare Pharmaceuticals Inc; Whippany NJ USA
| | - P. Zinzani
- Department of Hematology; Institute of Hematology "L. e A. Seràgnoli"- University of Bologna; Bologna Italy
| |
Collapse
|
19
|
Kaplan J, Gordon L, Infante J, Popat R, Rambaldi A, Madan S, Patel M, Gritti G, El-Sharkawi D, Chau I, Radford J, Perez De Oteyza J, Zinzani P, Iyer S, Faucette S, Sheldon-Waniga E, Stumpo K, Shou Y, Carpio C, Bosch F. TAK-659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT-3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE-ESCALATION AND EXPANSION COHORTS OF a PHASE 1 STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_60] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- J. Kaplan
- Department of Medicine; Northwestern University; Chicago USA
| | - L. Gordon
- Robert H Lurie Comprehensive Cancer Center; Northwestern University Feinberg School of Medicine; Chicago USA
| | - J. Infante
- Drug Development Unit; Sarah Cannon Research Institute/Tennessee Oncology; Nashville USA
| | - R. Popat
- NIHR Clinical Research Facility; UCLH; London UK
| | - A. Rambaldi
- Dipartimento di Oncologia ed Emato-Oncologia / Hematology and Bone Marrow Transplant Unit; Università degli Studi di Milano / Ospedale Papa Giovanni XXII; Bergamo Italy
| | - S. Madan
- Dipartimento di Oncologia ed Emato-Oncologia/Hematology and Bone Marrow Transplant Unit; Università degli Studi di Milano/Ospedale Papa Giovanni XXIII; Bergamo Italy
| | - M.R. Patel
- Hematology-Oncology; Florida Cancer Specialists/Sarah Cannon Research Institute; Sarasota USA
| | - G. Gritti
- Hematology and Bone Marrow Transplant Unit; Ospedale Papa Giovanni XXIII; Bergamo Italy
| | - D. El-Sharkawi
- Haematology; NIHR UCLH Clinical Research Facility; London UK
| | - I. Chau
- Department of Medicine; Royal Marsden Hospital; Surrey UK
| | - J. Radford
- Manchester Academic Health Science Centre; University of Manchester and the Christie NHS Foundation Trust; Manchester UK
| | | | - P. Zinzani
- Hematology, Institute of Hematology “Seragnoli”; University of Bologna; Bologna Italy
| | - S. Iyer
- Advanced Therapeutics, Institute of Academic Medicine; Houston Methodist Cancer Center; Houston USA
| | - S. Faucette
- Clinical Pharmacology; Takeda Pharmaceuticals International Co.; Cambridge USA
| | | | - K. Stumpo
- Oncology Clinical Research; Takeda Pharmaceuticals; Cambridge USA
| | - Y. Shou
- Oncology Clinical Research; Takeda Pharmaceuticals International Co.; Cambridge USA
| | - C. Carpio
- Hematology; University Hospital Vall d'Hebron; Barcelona Spain
| | - F. Bosch
- Hematology; University Hospital Vall d'Hebron; Barcelona Spain
| |
Collapse
|
20
|
Zinzani P, Ribrag V, Moskowitz C, Michot J, Kuruvilla J, Bartlett N, Balakumaran A, Chatterjee A, Chlosta S, Shipp M, Armand P. PHASE 1B STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (RRPMBCL): UPDATED RESULTS FROM THE KEYNOTE-013 TRIAL. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_50] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- P. Zinzani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - V. Ribrag
- Medicine, Institut Gustave Roussy; Villejuif France
| | - C.H. Moskowitz
- Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - J. Michot
- Medicine, Institut Gustave Roussy; Villejuif France
| | - J. Kuruvilla
- Oncology; Princess Margaret Cancer Centre and University of Toronto; Toronto Canada
| | - N. Bartlett
- Divisions of Hematology & Oncology; Washington University; St Louis USA
| | | | - A. Chatterjee
- Clinical Research, Merck & Co., Inc.; Kenilworth USA
| | - S. Chlosta
- Clinical Research, Merck & Co., Inc.; Kenilworth USA
| | - M.A. Shipp
- Division of Hematologic Neoplasia; Dana-Farber Cancer Institute; Boston USA
| | - P. Armand
- Lymphoma Clinical Research; Dana-Farber Cancer Institute; Boston USA
| |
Collapse
|
21
|
Pellegrini C, Pulsoni A, Rigacci L, Patti C, Gini G, Tani M, Rusconi C, Romano A, Vanazzi A, Hohaus S, Mazza P, Molica S, Corradini P, Gaudio F, Ronconi F, Pinto A, Pavone V, Volpetti S, Visentin A, Bonfichi M, Schiavotto C, Spina M, Carella A, Argnani L, Zinzani P. REAL LIFE EXPERIENCE WITH BRENTUXIMAB VEDOTIN: THE ITALIAN STUDY ON 234 RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- C. Pellegrini
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| | - A. Pulsoni
- Hematology, Department of Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - L. Rigacci
- Hematology Department; University and Hospital Careggi; Florence Italy
| | - C. Patti
- Hematology; Azienda Ospedali Riuniti Villa Sofia Cervello; Palermo Italy
| | - G. Gini
- Hematology; Ospedali Riuniti; Ancona Italy
| | - M. Tani
- Hematology; Santa Maria delle Croci Hospital; Ravenna Italy
| | - C. Rusconi
- Division of Hematology Niguarda Cancer Center; Niguarda Hospital; Milan Italy
| | - A. Romano
- Hematology, Azienda Policlinico-OVE; University of Catania; Catania Italy
| | - A. Vanazzi
- Division of Clinical Haemato-Oncology; IEO; Milan Italy
| | - S. Hohaus
- Institute of Hematology; Catholic Unicversityof the Sacred Heart; Rome Italy
| | - P. Mazza
- Department of Hematology-Oncology; Ospedale Moscati; Taranto Italy
| | - S. Molica
- Hematology; Azienda Ospedaliera Pugliese-Ciaccio; Catanzaro Italy
| | - P. Corradini
- Hematology; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy
| | - F. Gaudio
- Hematology; Policlinico di Bari; Bari Italy
| | - F. Ronconi
- Division of Hematology and Stem Cell Transplantation Unit; Cardarelli Hospital; Naples Italy
| | - A. Pinto
- Hematology-Oncology and Stem Cell Transplantation Unit; National Cancer Institute, Fondazione Pascale, IRCCS; Naples Italy
| | - V. Pavone
- Hematology; Ospedale G. Panico; Lecce Italy
| | - S. Volpetti
- Hematology; Azienda Sanitaria Universitaria Integrata; Udine Italy
| | - A. Visentin
- Hematology and Clinical Immunology Unit, Department of Medicine; University of Padua; Padova Italy
| | - M. Bonfichi
- Hematology; IRCCS Policlinico San Matteo; Pavia Italy
| | | | - M. Spina
- Division of Medical Oncology A; National Cancer Institute; Aviano Italy
| | - A. Carella
- Division of Hematology 1; IRCCS A.O.U. San Martino IST; Genoa Italy
| | - L. Argnani
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| | - P. Zinzani
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| |
Collapse
|
22
|
Dreyling M, Santoro A, Mollica L, Leppä S, Follows G, Lenz G, Kim W, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens D, Trevarthen D, Giurescu M, Liu L, Koechert K, Peña C, Cupit L, Yin S, Hiemeyer F, Garcia-Vargas J, Childs B, Zinzani P. COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL LYMPHOMA (CHRONOS-1). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_107] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Dreyling
- Medizinische Klinik und Poliklinik III; Klinikum der Universität München-Grosshadern; Munich Germany
| | - A. Santoro
- Department of Oncology and Hematology, Humanitas Cancer Center; Humanitas Clinical and Research Institute; Rozzano MI Italy
| | - L. Mollica
- Department of Hematology; Hôpital Maisonneuve-Rosemont-Montreal; Montreal Quebec Canada
| | - S. Leppä
- Department of Oncology; Helsinki University Central Hospital Cancer Center; Helsinki Finland
| | - G.A. Follows
- Department of Haematology; Cambridge University Hospitals NHS Foundation Trust Addenbrooke's Hospital; Cambridge UK
| | - G. Lenz
- Translational Oncology; University Hospital Münster; Münster Germany
| | - W. Kim
- Division of Hematology and Oncology, Department of Medicine; Sungkyunkwan University School of Medicine, Samsung Medical Center; Seoul Republic of Korea
| | - A. Nagler
- Hematology Division; Chaim Sheba Medical Center- Tel Aviv University; Tel-Hashomer Israel
| | - P. Panayiotidis
- Division of Hematology; Laikon University Hospital, National and Kapodistrian University of Athens; Athens Greece
| | - J. Demeter
- First Department of Internal Medicine, Division of Haematology; Semmelweis University; Budapest Hungary
| | - M. Özcan
- Department of Hematology; Ankara University School of Medicine; Ankara Turkey
| | - M. Kosinova
- Department of Hematology; Kemerovo Regional Clinical Hospital; Kemerovo Russian Federation
| | - K. Bouabdallah
- Service d'Hématologie et de Thérapie Cellulaire; University Hospital of Bordeaux; Pessac France
| | - F. Morschhauser
- Department of Hematology; CHRU - Hôpital Claude Huriez; Lille France
| | - D.A. Stevens
- Medical Oncology; Norton Cancer Institute; Louisville-KY USA
| | - D. Trevarthen
- Medical Oncology; Comprehensive Cancer Care and Research Institute of Colorado; Englewood-CO USA
| | - M. Giurescu
- Pharmaceutical Division, Bayer AG; Berlin Germany
| | - L. Liu
- Biomarkers; Bayer HealthCare Pharmaceuticals Inc; Whippany-NJ USA
| | - K. Koechert
- Pharmaceutical Division, Bayer AG; Berlin Germany
| | - C. Peña
- Biomarkers; Bayer HealthCare Pharmaceuticals Inc; Whippany-NJ USA
| | - L. Cupit
- Clinical Development; Bayer HealthCare Pharmaceuticals Inc; Whippany-NJ USA
| | - S. Yin
- Clinical Development; Bayer HealthCare Pharmaceuticals Inc; Whippany-NJ USA
| | - F. Hiemeyer
- Pharmaceutical Division, Bayer AG; Berlin Germany
| | - J. Garcia-Vargas
- Clinical Development; Bayer HealthCare Pharmaceuticals Inc; Whippany-NJ USA
| | - B.H. Childs
- Clinical Development; Bayer HealthCare Pharmaceuticals Inc; Whippany-NJ USA
| | - P. Zinzani
- Department of Hematology; Institute of Hematology "L. e A. Seràgnoli"- University of Bologna; Bologna Italy
| |
Collapse
|
23
|
Horwitz S, Whittaker S, Duvic M, Dummer R, Kim Y, Scarisbrick J, Quaglino P, Zinzani P, Wolter P, Eradat H, Sanches J, Ortiz-Romero P, Akilov O, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Wang Y, Palanca-Wessels M, Lin H, Liu Y, Little M, Prince H. RESPONSE BY STAGE IN CD30-POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_109] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- S. Horwitz
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - S. Whittaker
- St John's Institute of Dermatology, Guys and St Thomas NHS Foundation Trust; London UK
| | - M. Duvic
- Department of Dermatology; The University of Texas MD Anderson Cancer Center; Houston USA
| | - R. Dummer
- Department of Dermatology; University Hospital Zürich; Zürich Switzerland
| | - Y.H. Kim
- Department of Dermatology; Stanford University School of Medicine and Stanford Cancer Institute; Stanford USA
| | - J. Scarisbrick
- Department of Dermatology; University Hospital Birmingham; Birmingham UK
| | - P. Quaglino
- Department of Medical Sciences, Dermatologic Clinic; University of Turin; Turin Italy
| | - P. Zinzani
- Institute of Haematology; University of Bologna; Bologna Italy
| | - P. Wolter
- Department of General Medical Oncology; University Hospitals Leuven; Leuven Belgium
| | - H. Eradat
- Division of Hematology-Oncology; David Geffen School of Medicine at UCLA; Los Angeles USA
| | - J. Sanches
- Department of Dermatology; University of São Paulo Medical School; São Paulo Brazil
| | - P. Ortiz-Romero
- Department of Dermatology; University Hospital 12 de Octubre, Institute i+12 Medical School, University Complutense; Madrid Spain
| | - O. Akilov
- Department of Dermatology; University of Pittsburgh; Pittsburgh USA
| | - J. Trotman
- Haematology Department, Concord Repatriation General Hospital; University of Sydney; Sydney Australia
| | - K. Taylor
- Department of Haematology, ICON Cancer Care; South Brisbane Australia
| | - S. Dalle
- Department of Dermatology, Hospices Civils de Lyon; Claude Bernard Lyon 1 University; Lyon France
| | - M. Weichenthal
- Department of Dermatology; University Hospital of Schleswig-Holstein; Kiel Germany
| | - J. Walewski
- Department of Lymphoid Malignancies; Maria Sklodowska-Curie Institute and Oncology Centre; Warsaw Poland
| | - D. Fisher
- Department of Medical Oncology; Dana-Farber Cancer Institute; Boston USA
| | - Y. Wang
- Biometrics; Seattle Genetics, Inc.; Bothell USA
| | | | - H. Lin
- Biostatistics; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - Y. Liu
- Biostatistics; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - M. Little
- Oncology Clinical Research; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - H.M. Prince
- Division of Cancer Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology; The University of Melbourne; Melbourne Australia
| |
Collapse
|
24
|
Quirini F, Forti Parri S, Tonialini L, Stefoni V, Broccoli A, Pellegrini C, Marangon M, Bonfanti B, Argnani L, Zinzani P. HISTOLOGICAL VERIFICATION OF POSITIVE POSITRON EMISSION TOMOGRAPHY FINDINGS DURING THE FOLLOW-UP OF PATIENTS WITH MEDIASTINAL LYMPHOMA: LARGE EXPERIENCE ON 96 PATIENTS. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- F. Quirini
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| | - S. Forti Parri
- Thoracic Surgery Unit; Maggiore-Bellaria Hospital; Bologna Italy
| | - L. Tonialini
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| | - V. Stefoni
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| | - A. Broccoli
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| | - C. Pellegrini
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| | - M. Marangon
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| | - B. Bonfanti
- Thoracic Surgery Unit; Maggiore-Bellaria Hospital; Bologna Italy
| | - L. Argnani
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| | - P. Zinzani
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| |
Collapse
|
25
|
Rigacci L, Puccini B, Zinzani P, Kovalchuk S, Broccoli A, Evangelista A, Gioia D, Mannelli L, Castagnoli A, Santoro A, Bonfichi M, Rossi G, Anastasia A, Zaja F, Vitolo U, Pavone V, Pulsoni A, Gaidano G, Stelitano C, Salvi F, Rusconi C, Tani M, Freilone R, Borsatti E, Levis A. CLINICAL CHARACTERISTICS OF PATIENTS WITH NEGATIVE INTERIM-PET AND POSITIVE FINAL PET: DATA FROM THE PROSPECTIVE PET-ORIENTED HD0801 STUDY BY FONDAZIONE ITALIANA LINFOMI (FIL). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_19] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
| | | | - P. Zinzani
- Hematology; Ospedale Sant'Orsola Malpighi; Bologna Italy
| | | | - A. Broccoli
- Hematology; Ospedale Sant'Orsola Malpighi; Bologna Italy
| | | | - D. Gioia
- Hematology; Ospedale Alessandria; Alessandria Italy
| | | | | | - A. Santoro
- Hematology; Humanitas Cancer Center; Milan Italy
| | | | - G. Rossi
- Hematology; Ospedale Brescia; Brescia Italy
| | | | - F. Zaja
- Hematology; Ospedale Udine; Udine Italy
| | - U. Vitolo
- Hematology; AOU Città della Salute; Torino Italy
| | - V. Pavone
- Hematology; Ospedale Tricase; Tricase Italy
| | - A. Pulsoni
- Hematology; Università la Sapienza; Rome Italy
| | - G. Gaidano
- Hematology; Università Novara; Novara Italy
| | - C. Stelitano
- Hematology; Ospedale Reggio Calabria; Reggio Calabria Italy
| | - F. Salvi
- Hematology; Ospedale Alessandria; Alessandria Italy
| | - C. Rusconi
- Hematology; Ospedale Niguarda Ca' Grande; Milan Italy
| | - M. Tani
- Hematology; Ospedale Ravenna; Ravenna Italy
| | | | | | - A. Levis
- Hematology; Ospedale Alessandria; Alessandria Italy
| |
Collapse
|
26
|
Zinzani P, Dreyling M, Patnaik A, Morschhauser F, Benson A, Genvresse I, Miriyala A, Garcia-Vargas J, Childs B. INTEGRATED SAFETY DATA WITH COPANLISIB MONOTHERAPY FROM PHASE I AND II TRIALS IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN'S LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- P. Zinzani
- Department of Hematology; Institute of Hematology "L. e A. Seràgnoli"- University of Bologna; Bologna Italy
| | - M. Dreyling
- Medizinische Klinik und Poliklinik III; Klinikum der Universität München-Grosshadern; Munich Germany
| | - A. Patnaik
- Medical Oncology; South Texas Accelerated Research Therapeutics (START) Center for Cancer Care; San Antonio TX USA
| | - F. Morschhauser
- Department of Hematology; CHRU - Hôpital Claude Huriez; Lille France
| | - A. Benson
- Clinical Statistics; Bayer HealthCare Pharmaceuticals Inc; Whippany-NJ USA
| | - I. Genvresse
- Pharmaceutical Division, Bayer AG; Berlin Germany
| | - A. Miriyala
- Clinical Development; Bayer HealthCare Pharmaceuticals Inc; Whippany-NJ USA
| | - J. Garcia-Vargas
- Clinical Development; Bayer HealthCare Pharmaceuticals Inc; Whippany-NJ USA
| | - B.H. Childs
- Clinical Development; Bayer HealthCare Pharmaceuticals Inc; Whippany-NJ USA
| |
Collapse
|
27
|
Kim Y, Whittaker S, Horwitz S, Duvic M, Dummer R, Scarisbrick J, Quaglino P, Zinzani P, Wolter P, Wang Y, Palanca-Wessels M, Zagadailov E, Trepicchio W, Lin H, Little M, Prince H. 262 Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
28
|
Ferrara F, Barosi G, Venditti A, Angelucci E, Gobbi M, Pane F, Tosi P, Zinzani P, Tura S. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia 2013; 27:997-9. [DOI: 10.1038/leu.2012.303] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
29
|
Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, Kluin-Nelemans JC, Ladetto M, Le Gouill S, Iannitto E, Pileri S, Rodriguez J, Schmitz N, Wotherspoon A, Zinzani P, Zucca E. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013; 24:857-77. [PMID: 23425945 DOI: 10.1093/annonc/mds643] [Citation(s) in RCA: 223] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
To complement the existing treatment guidelines for all tumour types, ESMO organizes consensus conferences to focus on specific issues in each type of tumour. In this setting, a consensus conference on the management of lymphoma was held on 18 June 2011 in Lugano, next to the 11th International Conference on Malignant Lymphoma. The conference convened ∼30 experts from all around Europe, and selected six lymphoma entities to be addressed; for each of them, three to five open questions were to be addressed by the experts. For each question, a recommendation should be given by the panel, referring to the strength of the recommendation based on the level of evidence. This consensus report focuses on the three less common lymphoproliferative malignancies: marginal zone lymphoma, mantle cell lymphoma, and peripheral T-cell lymphomas. A first report had focused on diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukaemia.
Collapse
Affiliation(s)
- M Dreyling
- Department of Medicine III, University Hospital, LMU Munich, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Lopci E, Santi I, Tani M, Maffione AM, Montini G, Castellucci P, Stefoni V, Rubello D, Fonti C, Zinzani P, Fanti S. FDG PET and 90Y ibritumomab tiuxetan in patients with follicular lymphoma. Q J Nucl Med Mol Imaging 2010; 54:436-441. [PMID: 20823812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
AIM Despite its established utility in non-Hodgkin's lymphoma, not much is reported on FDG positron emission tomography (PET) with respect to radioimmunotherapy (RIT). In this paper we investigate its value in patients affected by follicular lymphoma (FL) before and after treatment with [90Y]Ibritumomab Tiuxetan (Zevalin(R)). METHODS We evaluated 38 relapsed or refractory FL patients. All had a PET scan performed before and 3 months after radioimmunotherapy. Final assessment was done 9 months post-RIT, including clinical evaluation, other imaging techniques and/or biopsy, when necessary. RESULTS At the first PET scan 20 patients out of 38 had a limited disease (nodal involvement on one side of the diaphragm: 7 above and 13 below), 11 patients had nodal findings on both sides of the diaphragm and the remaining 7 patients had both nodal and extra-nodal findings. At three months post-RIT, 21 patients (55%) were in complete remission, 13 patients (34%) had a partial response (PR) and four patients (11%) had a progression disease (PD). The corresponding rates at final assessment were all consistent with the 3-month evaluation: 55% CR, 13% PR and 32% PD. FDG PET scan revealed maximal predictive values. When comparing the disease extent at relapse and the response to treatment, we could testify a higher rate of CR (75%) in patients with limited disease, while in patients with diffused nodal and/or extra-nodal findings, it was more frequent a PR or PD (66%). CONCLUSION Our data are concordant with the expected results on RIT, and FDG PET is confirmed to be useful in assessing treatment response. Potential correlation can also be picked out between the disease extent at relapse and the CR rate, with reasonable PET predictivity for the final outcome.
Collapse
Affiliation(s)
- E Lopci
- S.Orsola-Malpighi Policlinic, Bologna, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Lopci E, Santi I, Derenzini E, Fonti C, Savelli G, Bertagna F, Bellò M, Botto B, Huglo D, Morschhauser F, Zinzani P, Fanti S. FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. Ann Oncol 2010; 21:1877-1883. [PMID: 20147744 DOI: 10.1093/annonc/mdq024] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND The aim of this study is the 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET) evaluation following radioimmunotherapy (RIT) with ibritumomab tiuxetan Y 90 in patients with non-Hodgkin's follicular lymphoma (FL). MATERIALS AND METHODS We retrospectively analyzed data from 59 relapsed or refractory FL patients treated with ibritumomab tiuxetan Y 90 in four different PET centers who had a PET scan carried out before and after RIT. Possible predictive factors of progression-free survival (PFS) were studied through univariate and multivariate analysis. RESULTS The post-RIT PET documented 45.8% complete responders (CR), 25.4% partial responders (PR) and 28.8% nonresponders [stable disease + progressive disease], with an overall survival of 71.2% (range 59.5%-90.9%). With a median follow-up period of 23 months, the univariate analysis documented a statistically significant relation between disease extent before RIT and response to treatment with respect to PFS (P = 0.015), while all the other prognostic factors showed no significant correlation. When carrying out the multivariate analysis, post-RIT PET resulted as the lonely independent predictor of PFS (P < 0.00001). CONCLUSIONS RIT is an effective therapy in FL patients, as confirmed in our study too. Disease extension before treatment and response to RIT, as assessed by FDG-PET, result as main predictors of PFS, with the post-RIT PET result being the only independent predictive factor.
Collapse
Affiliation(s)
- E Lopci
- PET Unit, Nuclear Medicine Department, University Hospital S. Orsola-Malpighi, Bologna
| | - I Santi
- PET Unit, Nuclear Medicine Department, University Hospital S. Orsola-Malpighi, Bologna
| | - E Derenzini
- Department of Hematology, 'L. Seragnoli' Institution, University Hospital S. Orsola-Malpighi, Bologna
| | - C Fonti
- PET Unit, Nuclear Medicine Department, University Hospital S. Orsola-Malpighi, Bologna
| | - G Savelli
- Department of Nuclear Medicine, Spedali Civili, Brescia
| | - F Bertagna
- Department of Nuclear Medicine, Spedali Civili, Brescia
| | - M Bellò
- Department of Nuclear Medicine
| | - B Botto
- Department of Hematology, University Hospital San Giovanni Battista, Torino, Italy
| | - D Huglo
- Department of Nuclear Medicine, University Hospital Claude Huriez, Lille, France
| | - F Morschhauser
- Department of Nuclear Medicine, University Hospital Claude Huriez, Lille, France
| | - P Zinzani
- Department of Hematology, 'L. Seragnoli' Institution, University Hospital S. Orsola-Malpighi, Bologna
| | - S Fanti
- PET Unit, Nuclear Medicine Department, University Hospital S. Orsola-Malpighi, Bologna.
| |
Collapse
|
32
|
Czuczman MS, Vose J, Zinzani P, Reeder C, Buckstein R, Haioun C, Bouabdallah R, Polikoff J, Ervin-Haynes A, Witzig T. Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: Results from an international study (NHL-003). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19504] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19504 Background: Patients with diffuse large-B-cell lymphoma (DLBCL) who are not cured with R-CHOP or high-dose chemotherapy with autologous stem cell rescue have a dismal prognosis. A recent phase II trial (NHL-002) of lenalidomide in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) demonstrated a 19% overall response rate (ORR) with a 7-month median duration of response (DR) in the subset of patients with DLBCL. A supporting international phase II trial (NHL-003) of single-agent lenalidomide was initiated for patients with relapsed or refractory aggressive NHL that had received at least one prior treatment and had measurable disease. Herein, we report the data from the DLBCL patients enrolled in this trial. Methods: Patients received 25 mg oral lenalidomide once daily on days 1–21 of every 28-day cycle and continued therapy until disease progression or toxicity. The 1999 IWLRC methodology was used to assess response and progression. Results: One hundred-three DLBCL patients were enrolled and were evaluable for response assessment. The median age was 66 years (21–87) and 70 patients (68%) were male. Median time from diagnosis was 2 years (0.4–18.6), patients had received a median of 3 prior treatment regimens (1–10) and 46 of the patients (45%) had received a prior stem cell transplant (DLBCL-stem cell). Response rates are shown in the Table . Grade 3 or 4 adverse events occurring in more than 5% of patients were neutropenia (34%), thrombocytopenia (18%), asthenia (9%), anemia (8%), leucopenia (7%), back pain (6%) and dyspnea (6%). Conclusions: This international study demonstrates that lenalidomide is active in heavily pre-treated patients with relapsed or refractory DLBCL and has manageable side effects. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- M. S. Czuczman
- Roswell Park Cancer Institute, Buffalo, NY; University of Nebraska, Omaha, NE; Institute of Hematology and Medical Oncology, Bologna, Italy; Mayo Clinic, Scottsdale, AZ; Toronto Sunnybrook Odette Cancer Center, Toronto, ON, Canada; Hôpital Henri Mondor, Créteil, France; Institute Paoli-Calmettes Haematology, Marseille, France; Kaiser Permanente Medical Group, Southern California, CA; Celgene Corporation, Summit, NJ; Mayo Clinic, Rochester, MN
| | - J. Vose
- Roswell Park Cancer Institute, Buffalo, NY; University of Nebraska, Omaha, NE; Institute of Hematology and Medical Oncology, Bologna, Italy; Mayo Clinic, Scottsdale, AZ; Toronto Sunnybrook Odette Cancer Center, Toronto, ON, Canada; Hôpital Henri Mondor, Créteil, France; Institute Paoli-Calmettes Haematology, Marseille, France; Kaiser Permanente Medical Group, Southern California, CA; Celgene Corporation, Summit, NJ; Mayo Clinic, Rochester, MN
| | - P. Zinzani
- Roswell Park Cancer Institute, Buffalo, NY; University of Nebraska, Omaha, NE; Institute of Hematology and Medical Oncology, Bologna, Italy; Mayo Clinic, Scottsdale, AZ; Toronto Sunnybrook Odette Cancer Center, Toronto, ON, Canada; Hôpital Henri Mondor, Créteil, France; Institute Paoli-Calmettes Haematology, Marseille, France; Kaiser Permanente Medical Group, Southern California, CA; Celgene Corporation, Summit, NJ; Mayo Clinic, Rochester, MN
| | - C. Reeder
- Roswell Park Cancer Institute, Buffalo, NY; University of Nebraska, Omaha, NE; Institute of Hematology and Medical Oncology, Bologna, Italy; Mayo Clinic, Scottsdale, AZ; Toronto Sunnybrook Odette Cancer Center, Toronto, ON, Canada; Hôpital Henri Mondor, Créteil, France; Institute Paoli-Calmettes Haematology, Marseille, France; Kaiser Permanente Medical Group, Southern California, CA; Celgene Corporation, Summit, NJ; Mayo Clinic, Rochester, MN
| | - R. Buckstein
- Roswell Park Cancer Institute, Buffalo, NY; University of Nebraska, Omaha, NE; Institute of Hematology and Medical Oncology, Bologna, Italy; Mayo Clinic, Scottsdale, AZ; Toronto Sunnybrook Odette Cancer Center, Toronto, ON, Canada; Hôpital Henri Mondor, Créteil, France; Institute Paoli-Calmettes Haematology, Marseille, France; Kaiser Permanente Medical Group, Southern California, CA; Celgene Corporation, Summit, NJ; Mayo Clinic, Rochester, MN
| | - C. Haioun
- Roswell Park Cancer Institute, Buffalo, NY; University of Nebraska, Omaha, NE; Institute of Hematology and Medical Oncology, Bologna, Italy; Mayo Clinic, Scottsdale, AZ; Toronto Sunnybrook Odette Cancer Center, Toronto, ON, Canada; Hôpital Henri Mondor, Créteil, France; Institute Paoli-Calmettes Haematology, Marseille, France; Kaiser Permanente Medical Group, Southern California, CA; Celgene Corporation, Summit, NJ; Mayo Clinic, Rochester, MN
| | - R. Bouabdallah
- Roswell Park Cancer Institute, Buffalo, NY; University of Nebraska, Omaha, NE; Institute of Hematology and Medical Oncology, Bologna, Italy; Mayo Clinic, Scottsdale, AZ; Toronto Sunnybrook Odette Cancer Center, Toronto, ON, Canada; Hôpital Henri Mondor, Créteil, France; Institute Paoli-Calmettes Haematology, Marseille, France; Kaiser Permanente Medical Group, Southern California, CA; Celgene Corporation, Summit, NJ; Mayo Clinic, Rochester, MN
| | - J. Polikoff
- Roswell Park Cancer Institute, Buffalo, NY; University of Nebraska, Omaha, NE; Institute of Hematology and Medical Oncology, Bologna, Italy; Mayo Clinic, Scottsdale, AZ; Toronto Sunnybrook Odette Cancer Center, Toronto, ON, Canada; Hôpital Henri Mondor, Créteil, France; Institute Paoli-Calmettes Haematology, Marseille, France; Kaiser Permanente Medical Group, Southern California, CA; Celgene Corporation, Summit, NJ; Mayo Clinic, Rochester, MN
| | - A. Ervin-Haynes
- Roswell Park Cancer Institute, Buffalo, NY; University of Nebraska, Omaha, NE; Institute of Hematology and Medical Oncology, Bologna, Italy; Mayo Clinic, Scottsdale, AZ; Toronto Sunnybrook Odette Cancer Center, Toronto, ON, Canada; Hôpital Henri Mondor, Créteil, France; Institute Paoli-Calmettes Haematology, Marseille, France; Kaiser Permanente Medical Group, Southern California, CA; Celgene Corporation, Summit, NJ; Mayo Clinic, Rochester, MN
| | - T. Witzig
- Roswell Park Cancer Institute, Buffalo, NY; University of Nebraska, Omaha, NE; Institute of Hematology and Medical Oncology, Bologna, Italy; Mayo Clinic, Scottsdale, AZ; Toronto Sunnybrook Odette Cancer Center, Toronto, ON, Canada; Hôpital Henri Mondor, Créteil, France; Institute Paoli-Calmettes Haematology, Marseille, France; Kaiser Permanente Medical Group, Southern California, CA; Celgene Corporation, Summit, NJ; Mayo Clinic, Rochester, MN
| |
Collapse
|
33
|
Gianni AM, Rambaldi A, Zinzani P, Levis A, Brusamolino E, Pulsoni A, Liberati M, Pogliani E, Cortelazzo S, Valagussa P. Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8506] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
34
|
Pfreundschuh MG, Hensel M, Cavallin-Stahl E, Vasova I, Kvaloey S, Gill D, Walewski J, Zinzani P, Pettengell R, Kuhnt E. Prognostic significance of maximal tumor size (MTS) in young patients with good-prognosis diffuse large B-cell lymphoma (DLBCL) treated with CHOP-like chemotherapy with and without rituximab: Analysis of the MabThera International Trial Group (MInT) study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.8053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8053 Purpose: To determine the impact of MTS in young (18 to 60 years) patients with DLBCL and aaIPI=0,1. Patients and Methods: Outcome of patients treated with CHOP-like chemotherapy with (R-CHEMO) or without rituximab (CHEMO) was analyzed according to MTS. Results: A Martingale residual analysis revealed a linear negative prognostic impact of MTS on event-free (EFS) and overall (OS) survival. The hazard ratios for MTS per centimeter increase were significant for EFS (1.07; 95%-CI: 1.04–1.11; p<0.001) and OS (1.11; 95%-CI: 1.06–1.16; p<0.001). CHEMO 3-year EFS rates ranged between 78% for MTS <5cm and 41% for MTS >10cm. R-CHEMO 3-year EFS ranged from 83% (MTS <5cm) to 73% (MTS >=10cm). CHEMO 3-year OS rates decreased from 93% (MTS <5cm) to 74% (MTS >=10cm). R-CHEMO 3-year OS decreased from 98% (MTS <5cm) to 85% (MTS >=10cm). With CHEMO, any cut-off point between 5 and 10 cm separated a thus defined “non-bulky” from a “bulky” population with a 3-year EFS difference >20% (p<0.0001) and OS difference >12% (p<0.003), while with R-CHEMO only cut-off points >=10cm separated two populations with a significant EFS difference (9.1%; p=0.047), and cut-off points >=6cm discriminated two populations with a significant OS difference (7.6%-11.3%; p=0.037–0.0009). Conclusion: Due to the linear prognostic impact of MTS on outcome, cut-off points for “bulky” disease can be set rather arbitrarily between 5 and 10cm depending on clinical considerations. Rituximab reduces, but does not eliminate the negative prognostic impact of MTS in young patients with good-prognosis DLBCL. [Table: see text]
Collapse
Affiliation(s)
- M. G. Pfreundschuh
- Universitatskliniken des Saarlandes, Homburg, Germany; Ruprecht-Karls-Universitaet, Heidelberg, Germany; University Hospital, Lund, Sweden; HOK, FN, Brno-Bohunice, Czech Republic; Radiumhospitalet, Oslo, Norway; Princess Alexandra Hospital, Woolloogabba, Australia; Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland; Policlinico S. Orsola, Bologna, Italy; St. George′s Hospital Medical School, London, United Kingdom; IMISE, Leipzig, Germany
| | - M. Hensel
- Universitatskliniken des Saarlandes, Homburg, Germany; Ruprecht-Karls-Universitaet, Heidelberg, Germany; University Hospital, Lund, Sweden; HOK, FN, Brno-Bohunice, Czech Republic; Radiumhospitalet, Oslo, Norway; Princess Alexandra Hospital, Woolloogabba, Australia; Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland; Policlinico S. Orsola, Bologna, Italy; St. George′s Hospital Medical School, London, United Kingdom; IMISE, Leipzig, Germany
| | - E. Cavallin-Stahl
- Universitatskliniken des Saarlandes, Homburg, Germany; Ruprecht-Karls-Universitaet, Heidelberg, Germany; University Hospital, Lund, Sweden; HOK, FN, Brno-Bohunice, Czech Republic; Radiumhospitalet, Oslo, Norway; Princess Alexandra Hospital, Woolloogabba, Australia; Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland; Policlinico S. Orsola, Bologna, Italy; St. George′s Hospital Medical School, London, United Kingdom; IMISE, Leipzig, Germany
| | - I. Vasova
- Universitatskliniken des Saarlandes, Homburg, Germany; Ruprecht-Karls-Universitaet, Heidelberg, Germany; University Hospital, Lund, Sweden; HOK, FN, Brno-Bohunice, Czech Republic; Radiumhospitalet, Oslo, Norway; Princess Alexandra Hospital, Woolloogabba, Australia; Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland; Policlinico S. Orsola, Bologna, Italy; St. George′s Hospital Medical School, London, United Kingdom; IMISE, Leipzig, Germany
| | - S. Kvaloey
- Universitatskliniken des Saarlandes, Homburg, Germany; Ruprecht-Karls-Universitaet, Heidelberg, Germany; University Hospital, Lund, Sweden; HOK, FN, Brno-Bohunice, Czech Republic; Radiumhospitalet, Oslo, Norway; Princess Alexandra Hospital, Woolloogabba, Australia; Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland; Policlinico S. Orsola, Bologna, Italy; St. George′s Hospital Medical School, London, United Kingdom; IMISE, Leipzig, Germany
| | - D. Gill
- Universitatskliniken des Saarlandes, Homburg, Germany; Ruprecht-Karls-Universitaet, Heidelberg, Germany; University Hospital, Lund, Sweden; HOK, FN, Brno-Bohunice, Czech Republic; Radiumhospitalet, Oslo, Norway; Princess Alexandra Hospital, Woolloogabba, Australia; Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland; Policlinico S. Orsola, Bologna, Italy; St. George′s Hospital Medical School, London, United Kingdom; IMISE, Leipzig, Germany
| | - J. Walewski
- Universitatskliniken des Saarlandes, Homburg, Germany; Ruprecht-Karls-Universitaet, Heidelberg, Germany; University Hospital, Lund, Sweden; HOK, FN, Brno-Bohunice, Czech Republic; Radiumhospitalet, Oslo, Norway; Princess Alexandra Hospital, Woolloogabba, Australia; Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland; Policlinico S. Orsola, Bologna, Italy; St. George′s Hospital Medical School, London, United Kingdom; IMISE, Leipzig, Germany
| | - P. Zinzani
- Universitatskliniken des Saarlandes, Homburg, Germany; Ruprecht-Karls-Universitaet, Heidelberg, Germany; University Hospital, Lund, Sweden; HOK, FN, Brno-Bohunice, Czech Republic; Radiumhospitalet, Oslo, Norway; Princess Alexandra Hospital, Woolloogabba, Australia; Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland; Policlinico S. Orsola, Bologna, Italy; St. George′s Hospital Medical School, London, United Kingdom; IMISE, Leipzig, Germany
| | - R. Pettengell
- Universitatskliniken des Saarlandes, Homburg, Germany; Ruprecht-Karls-Universitaet, Heidelberg, Germany; University Hospital, Lund, Sweden; HOK, FN, Brno-Bohunice, Czech Republic; Radiumhospitalet, Oslo, Norway; Princess Alexandra Hospital, Woolloogabba, Australia; Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland; Policlinico S. Orsola, Bologna, Italy; St. George′s Hospital Medical School, London, United Kingdom; IMISE, Leipzig, Germany
| | - E. Kuhnt
- Universitatskliniken des Saarlandes, Homburg, Germany; Ruprecht-Karls-Universitaet, Heidelberg, Germany; University Hospital, Lund, Sweden; HOK, FN, Brno-Bohunice, Czech Republic; Radiumhospitalet, Oslo, Norway; Princess Alexandra Hospital, Woolloogabba, Australia; Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland; Policlinico S. Orsola, Bologna, Italy; St. George′s Hospital Medical School, London, United Kingdom; IMISE, Leipzig, Germany
| |
Collapse
|
35
|
Lemoli RM, Rosti G, Visani G, Gherlinzoni F, Miggiano MC, Fortuna A, Zinzani P, Tura S. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma. J Clin Oncol 1996; 14:3018-25. [PMID: 8918500 DOI: 10.1200/jco.1996.14.11.3018] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
PURPOSE To assess the safety, tolerability, and hematopoietic efficacy of sequential and concomitant administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human interleukin-3 (rhIL-3), to accelerate reconstitution of hematopoiesis following myeloablative chemotherapy and autologous bone marrow transplantation (ABMT) for heavily pretreated lymphoma patients. PATIENTS AND METHODS Fifty-four consecutive patients with refractory or relapsed non-Hodgkin's lymphoma (NHL; n = 30) and Hodgkin's disease (HD; n = 24) were studied. Two different conditioning regimens were used for ABMT: carmustine, cyclophosphamide, etoposide, and cytarabine (BAVC) and carmustine, melphalan, etoposide, and cytarabine (BEAM) for NHL and HD, respectively. Patients were enrolled sequentially onto one of three treatment groups: group 1, G-CSF (5 micrograms/kg/d subcutaneously [SC]) from day +1 after reinfusion of autologous marrow (n = 23); group 2, G-CSF from day +1 combined with IL-3 (10 micrograms/kg/d SC) from day +6 (n = 22, overlapping schedule); and group 3, G-CSF treatment discontinued at day +6 before initiation of IL-3 administration (n = 9, sequential schedule). In the three groups, growth factor(s) was administered until the granulocyte count was greater than 0.5 x 10(9)/L for 3 consecutive days. RESULTS The study cytokines were generally well tolerated. No side effects were observed when G-CSF was given alone. Four of 31 patients (12.9%) who received SC IL-3 had one severe adverse event defined as World Health Organization (WHO) grade 3 to 4 toxicity (fever, n = 2; pulmonary toxicity, n = 2) and were withdrawn from the study. Groups 2 and 3 did not differ as for treatment tolerability, whereas we observed a trend toward a faster hematopoietic recovery when IL-3 was administered concomitant with G-CSF from day 6 (ie, group 2). Pooled together, patients who received IL-3 showed a median time to achieve a granulocyte count greater than 0.1 and greater than 0.5 x 10(9)/L of 8 and 11 days, respectively. The median time to an unsupported platelet count greater than 20 and 50 x 10(9)/L was 15 and 20 days, respectively, and only one patient did not reach a normal platelet count. The median number of days to hospital discharge was 16 after ABMT (range, 12 to 29). When the hematologic reconstitution of patients in groups 2 and 3 was compared with that of patients in group 1, the addition of IL-3 resulted in a significant improvement of multilineage hematopoietic recovery, lower transfusion requirements, a lower number of documented infections, and shorter hospitalizations. CONCLUSION We conclude that the combination of G-CSF and IL-3 is safe and well tolerated in intensively pretreated lymphoma patients, undergoing ABMT and results in rapid hematopoietic recovery following myeloablative chemotherapy.
Collapse
Affiliation(s)
- R M Lemoli
- Institute of Hematology Seràgnoli, University of Bologna, Italy
| | | | | | | | | | | | | | | |
Collapse
|